The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity Liposarcoma

Abstract

In patients with large, high-grade, primary extremity liposarcoma; DOX is not associated with improved DSS and IF is associated with an improved DSS. Treatment with IF should be considered in patients with high-risk primary extremity liposarcoma.

References

Page 1

	Year	Citations
Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. Peter W. T. Pisters, Denis H. Y. Leung, James M. Woodruff, Journal of Clinical Oncology	1996	1.2K
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data The Lancet Surgical OncologyHealth SciencesMalignant DiseaseMedicineMetronomic Therapy	1997	1K
Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial S. Frustaci, F. Gherlinzoni, Antonino De Paoli, Journal of Clinical Oncology	2001	702
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data Jayne F. Tierney, Richard Sylvester Digital Access to Libraries Surgical OncologyHealth SciencesMalignant DiseaseMedicineMetronomic Therapy	1997	692
Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma Samuel Singer, Cristina R. Antonescu, Elyn Riedel, Annals of Surgery	2003	657
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor Peter Tontonoz, Samuel Singer, Barry M. Forman, Proceedings of the National Academy of Sciences	1997	647
Dedifferentiated Liposarcoma Walter H. Henricks, Young Chae Chu, John R. Goldblum, The American Journal of Surgical Pathology	1997	618
Pathology and genetics of tumors of soft tissue and bone Christopher D.�M. Fletcher Medical Entomology and Zoology Tumoral PathologyCancer PathologySoft Tissue SurgeryHistopathologyPathology	2002	553
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma George D. Demetri, Christopher D.�M. Fletcher, Elisabetta Mueller, Proceedings of the National Academy of Sciences	1999	490
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Karen H. Antman, John Crowley, S P Balcerzak, Journal of Clinical Oncology	1993	477

Page 1